How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Apalutamide with androgen deprivation therapy for treating prostate cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about apalutamide

Marketing authorisation indication

2.1 Apalutamide (Erleada, Janssen) is indicated:

  • 'in adult men for the treatment of non-metastatic castration-resistant prostate cancer in adults who are at high risk of developing metastatic disease

  • in adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The price for apalutamide is £2,735 per pack of 112 tablets, each containing 60 mg of the active ingredient (excluding VAT; BNF online, March 2021). The company has a commercial arrangement, which would have applied if the technology had been recommended.